Symbiotec Pharmalab launches ₹1,757 cr IPO August 24 to 27
Symbiotec Pharmalab is launching its ₹1,757 crore IPO this week, running from August 24 to 27.
Shares are priced between ₹933 and ₹988, and you'll need to apply for at least 15 shares if you're interested.
The offering includes both a fresh issue and a big sell-off by current shareholders like Satwani Holdings and Rosewood Investments.
Anchors subscribe ₹526.2 cr pre IPO
Before the IPO, Symbiotec pulled in ₹526.2 crore from major anchor investors such as Citigroup Global Markets and BNP Paribas.
The fresh funds will help pay off debt and support company growth; proceeds from the sale go to existing shareholders cashing out.
With fiscal 2025 revenue at ₹751.6 crore and profit at ₹96.8 crore, analysts are recommending the IPO thanks to Symbiotec's global leadership in steroid APIs and strong vertical integration, valuing the company at ₹6,348.5 crore post-issue market capitalisation.